Neurocrine Biosciences
NBIX
Neurocrine Biosciences (NBIX) news
Recent news
Nexera Pharma Co., Ltd.: Nexera Pharma's partner Neurocrine Biosciences receives IND acceptance from FDA for phase 2 study of NBI-1117567 for Alzheimer's cognition
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with Nxera Pharma, has announced the initiation of a Phase 2 clinical study for NBI-1117567, an investigational M1-preferring muscarinic agonist, targeting Alzheimer’s cognition. The study is expected to begin in 2026, following the…
AInvest Wire · 5d agoNeurocrine Biosciences, Inc: Truist Securities raises target price to $213 from $200
AInvest Wire · Aug 3, 2026Neurocrine Biosciences, Inc: RBC raises target price to $198 from $195
AInvest Wire · Jul 31, 2026Neurocrine Biosciences, Inc: Ingrezza (valbenazine) 2026 net sales guidance raised to $2.825 to $2.875 billion
AInvest Wire · Jul 30, 2026Neurocrine Biosciences Q2 product sales USD 954.3 million
AInvest Wire · Jul 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.